Use of systemic steroids during pulmonary exacerbations in children and adolescent with Cystic fibrosis

Danish Abdul Aziz, Fatima Siddique, Shahira Shahid, Anusha Alam, Namrah Aziz

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine the role of systemic steroids in cystic fibrosis patients and its effects on pulmonary exacerbation in children and adolescents. Method: The retrospective cohort study was conducted at the Aga Khan University Hospital, Karachi, and comprised data from January 2015 to December 2019 of cystic fibrosis patients aged 3-18 years hospitalised with pulmonary exacerbations. The patients were divided into systemic steroid group A and non-systemic steroid group B. Patients in group A received parenteral steroids during acute exacerbation of cystic fibrosis in the first two weeks of admission, while those in group B did not receive systemic steroids. Length of hospital stay and number of days on oxygen support were compared between the groups. Data was analysed using SPSS 22. Result: Of the 124 patient charts evaluated, 84(67.7%) were included; 40(47.6%) in group A and 44(52.4%) in group B. There were no significant differences between the groups related to age, age at diagnosis, weight, height, and pulmonary exacerbations (p>0.05). Group A had significantly fewer days on oxygen support compared to group B (p<0.001), but there was inter-group difference in mean length of hospital stay (p=0.53). Conclusion: Systemic steroid usage during hospitalisation for acute exacerbation of cystic fibrosis was associated with decreased duration of oxygen requirement with standard treatment.

Original languageEnglish (US)
Pages (from-to)1525-1528
Number of pages4
JournalJournal of the Pakistan Medical Association
Volume72
Issue number8
DOIs
Publication statusPublished - Aug 2022

Keywords

  • Oxygen support. (JPMA 72: 1525; 2022)
  • Pulmonary exacerbation
  • Systemic corticosteroids

Fingerprint

Dive into the research topics of 'Use of systemic steroids during pulmonary exacerbations in children and adolescent with Cystic fibrosis'. Together they form a unique fingerprint.

Cite this